Biopharmaceutical company developing life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss.
03 July 2017
Sensorion Amends Existing Convertible Notes Program Under More Favorable Terms with €10 Million in Financing Read
08 June 2017
Sensorion Announces Results from 2017 Annual General Meeting: Appointments of Dominique Costantini and Nawal Ouzren to Company’s Board of Directors Approved Read
Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more
Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more
Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more